Clinical Trials Sponsored by Teva Pharmaceuticals Development, Inc.

Total 807 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

Congestive Heart Failure

Canada, United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder (JUNIPER)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Poland, Bulgaria, France
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Poland, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Post Traumatic Stress Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

Smoking Cessation

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Borderline Personality Disorder

United States, Spain, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Drug-drug Interaction

Australia
Otsuka Pharmaceutical Development & Commercialization...

Completed

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Adult ADHD

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Tourette's Disorder

Germany, United States, Bulgaria, Romania, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Taiwan, Korea, Republic of, Mexico, Canada, Hungary
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Germany, Taiwan, Korea, Republic of, Mexico, Hungary, Bulgaria, Ukraine, Romania, Canada
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

Tourette's Disorder (TD)

United States, Canada, Hungary
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation (CADENCE 215)

Atrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

United States, Italy, Germany, Netherlands, Spain, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC)

Pancreatic Cancer

Belgium, Canada, France, Russian Federation, Italy, United States, Australia, Austria, Germany, Romania, Hungary, Poland, United Kingdom, Ireland, Czech Republic
Otsuka Pharmaceutical Development & Commercialization...

Completed

International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia

Hyponatremia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (Pyxis)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Canada, Slovakia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (STEP-D222)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Open-label, Safety and Tolerability Study (STEP 210)

Schizophrenia

United States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR)

Acute Schizophrenia

Korea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tic Disorder | Tourette's Disorder

United States, Canada, Hungary, Italy
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE US)

Schizophrenia

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Multiple Myeloma

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

Atopic Dermatitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome

Schizophrenia | Schizoaffective Disorder | Metabolic Syndrome | Bipolar I Disorder

Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole and Effexor XR Drug Interaction Study

Healthy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole and Lexapro Drug Interaction Study

Healthy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (ASPIRE)

Schizophrenia

Korea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
Otsuka Pharmaceutical Development & Commercialization...

Completed

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (ASPIRE)

Schizophrenia

United States, Argentina, Bulgaria, India, Malaysia, Mexico, Philippines, Romania, Russian Federation, Serbia, Slovakia, Taiwan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Congestive Heart Failure

United States
COUR Pharmaceutical Development Company, Inc.

Recruiting

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Myasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MG

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Mexico, Netherlands, Slovakia, Slovenia, Spain, Ireland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Bulgaria, Denmark, Estonia, Greece, Poland, Portugal, Puerto Rico, United Kingdom, Germany, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Schizophrenia | Major Depressive Disorder | Mental Disorder | Bipolar I Disorder

United States

Clinical Trials Sponsored by Teva Pharmaceuticals Development, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations